Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
FxWirePro- Major Crypto levels and bias summary 
Bitcoin Defies Gravity Above $93K Despite Missing Retail FOMO – ETF Inflows Return & Whales Accumulate: Buy the Dip to $100K 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Ethereum Ignites: Fusaka Upgrade Unleashes 9× Scalability as ETH Holds Strong Above $3,100 – Bull Run Reloaded 
Bitcoin Smashes $93K as Institutions Pile In – $100K Next? 
India’s IT Sector Faces Sharp 2025 Valuation Reset as Mid-Caps Outshine Large Players 
MEI Pharma has taken a major step, becoming the first publicly traded firm on a national exchange to include Litecoin (LTC) as a major treasury reserve asset. Starting with a $100 million private placement (PIPE) on July 18, 2025, which concluded on July 22, 2025, this approach specifically allocated for acquiring Litecoin is the revenues from this agreement, which amount to about $100 million from the sale of 29 2 million shares at $3. 42 apiece. Key figures in the crypto sector, including Litecoin founder Charlie Lee, crypto trading company GSR, and the Litecoin Foundation, have shown great support for this project. Charlie Lee also joins MEI Pharma's board of directors while GSR acts as the company's digital asset and treasury management advisor.
The company's commitment to this strategy stretches further as MEI Pharma is actively seeking an additional $100 million through another equity raise, therefore possibly bringing their total allocation to LTC for corporate reserves to $200 million. Already the market has felt the effects of this revolutionary choice. Five days after the announcement, MEIP's stock saw a remarkable surge of more than 100%, reaching $9 before settling lately at $6. 86, so showing great investor confidence. Driven by positive attitude around this institutional approval, Litecoin's price has also experienced a substantial increase, rising 21. 9% over the past week to trade at $117. 30.
MEI Pharma's embrace of Litecoin is seen by analysts as a watershed event that confirms the asset value of LTC and possibly clears the way for more general institutional acceptance in conventional finance. With expectations that more adoption and possible ETF approvals could result in additional price increases and mainstream recognition, this move is projected to improve market confidence in Litecoin and increase its profile. Eventually, MEI Pharma's ground-breaking move is viewed as redefining digital asset integration for public corporations, thereby transforming the corporate treasury scene with regard to cryptocurrencies.
